Venus Remedies Ltd, a fastest growing research based pharmaceutical company in the country has marked its presence in the region of Australasia by receiving a patent from Commissioner of Patents , Trademarks & Design, Intellectual Property office of New Zealand for its antibiotic Potentox, a fixed dose combination of cefepime and amikacin. This unique combination of a cephalosporin with aminoglycoside is a super specialty product indicated for the treatment of Hospital acquired pneumonia, community acquired pneumonia and Febrile Neutropenia.
Dr. Manu Chaudhary, JMD, Venus Remedies Ltd. says, “This patent will give us exclusive marketing rights in New Zealand where post registration we expect to generate handsome revenues from this product which will add to the growth in top line and bottom line of the company”
Potentox for which Venus already has patent from South Korea , India and South Africa is contributing more than Rs. 120 million p.a to the total revenues of the company and is expected to grow at the rate of 30% to 40% Y-o-Y basis due to global registrations and Patent grants in pipe line from other markets.
There is a fair amount of bacterial-resistance towards the conventional antibiotics like penicillin, ampicillin-clavulanate, erythromycin, cefuroxime (Ceftin), ofloxacin (Floxin), and trimethoprim-sulfanethoxazole . This has led to increase in treatment cost for pneumonia. The major generators of costs for community-acquired pneumonia (CAP) in New Zealand adults are the number of hospitalisations (particularly for the group aged 65 years and over) and loss of productivity. The annual cost estimates were to be $63 million.
According to estimates of a journal of New Zealand medical association, the proportion of pneumonia cases hospitalized are 20% in those aged 15–64 years, 40% in those aged 65–74 years, 60% in those aged 75–84 years, and 70% in those aged over 85 years (31% over all ages). According to a WHO estimates, on an average, 30 % of adults in developed nations who have a pneumococcal pneumonia die from the infection.
“Venus Medicine Research Centre has developed Potentox taking into consideration these aspects. As a result, there is negligible bacterial resistance to Potentox, thumping its success rate to more than 95% and reduction in hospitalization time to 7-10 days from conventional 14-21 days and bringing down the treatment cost substantially,” said Dr. Manu Chaudhary.
The combined pharmaceutical market of Australia / New Zealand is US $ 8.3 billion growing at the rate of 7 %/annum. Global Data’s analysis suggests that the global pneumonia market was worth $1.4 billion in 2009.
Venus has a long history of pioneering developments in the areas of intensive care. The product Potentox was launched in the Indian market after completion all preclinical and multicentric Phase III clinical trials on more than 300 patients after DCGI approval. After the launch Post Marketing Phase IV studies were also conducted to re-establish the safety of drug. The product has potential to reduce the toxicity caused by aminoglycosides and disease condition. Venus launched Potentox in Indian market three years back. The product has already been used by more than 50,000 patients across India and has proved to be a highly effective for the patients. The company is also planning to launch pediatric version of this medicine and has already applied with DCGI seeking permission to conduct Phase III multi centric randomized pediatric clinical trials.
Company is on the verge of grant of patent of Potentox from other countries and is actively pursuing talks for Exclusive Market licensing of Potentox in all those countries where patent of the product has been granted.
About Venus Remedies Ltd.:
Venus Remedies Ltd is research and development driven pharmaceutical manufacturing company. Among the top 50 Indian Pharma companies of India, the company has out paced most Indian pharmaceutical companies in its growth and value creation over the past few years.
Driven by a top class team of managers and motivators this organization is counted as one of the most professional companies of India and a preferred place for top innovators and managers to join the bandwagon of the globally significant Indian Pharma industry.
Venus Remedies Ltd is BSE & NSE listed company with turnover of 310 crores (FY 2010) is present in 60 regulated and semi-regulated countries, actively exporting to more than 20 countries.
The company has two manufacturing locations in India and one in Germany. Venus is top class manufacturer of Oncological and Cephalosporin Injectable products following EU-GMP norms for all is activities.
Venus has a broad range of products catering to critical care segment in parenterals like cephalosporins, carbapenems and oncology drugs in lyophilized form, infusions and small volume parenterals .
The research team of Venus has proved itself to be a power house of innovation by filing many international patents for sophisticated formulations of anti-biotics and oncological therapeutics.
In May 2010 Venus has won Gold medal for the best innovation under the India Innovation Growth Program 2010 organized by FICCI, Department of Science and Technology Govt. of India, Lockheed Martin Corporation, IC2 Institute at the University of Texas and Indo-US Science &Technology Forum. Having won this award company will be assisted by US-based Lockheed Martin Foundation and the University of Texas to commercialise its advanced wound care product Ampucare in the US market.
Venus Remedies is aiming to create intellectual property wealth of one billion US dollor.
